LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Panel of Bloodstream MicroRNAs Predicts Damage from Radiation Exposure

By LabMedica International staff writers
Posted on 25 May 2015
A panel of microRNAs (miRNAs) that can be measured in blood samples is able to predict the extent of long-term radiation injury and likelihood of survival following exposure to high doses of radiation.

Accidental radiation exposure is a threat to human health that necessitates effective clinical planning and diagnosis. Minimally invasive biomarkers that can predict long-term radiation injury are urgently needed for optimal management after exposure to high levels of radiation.

Investigators at Dana-Farber Cancer Institute (Boston, MA, USA) have identified serum miRNA signatures that indicate long-term impact of total body irradiation (TBI) in mice when measured within 24 hours of exposure.

MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer. MiRNAs are made in cells, but some may be detected in the bloodstream.

The investigators systematically assessed the impact of TBI on the bone marrow's blood-cell production system to determine a correlation of residual hematopoietic stem cells (HSCs) with increasing doses of radiation. In addition, they found that 68 of 170 miRNAs detected in blood serum changed with radiation exposure. This number was reduced to a panel that acted as a "signature" of radiation dose.

The investigators reported that mice exposed to sub-lethal (6.5 Gy) and lethal (8.0 Gy) doses of radiation were physically indistinguishable for three to four weeks after exposure. In contrast, a serum miRNA signature was detectable 24 hours after radiation exposure that consistently differentiated these two populations.

By using a radioprotective agent before exposure or radiation mitigation after lethal radiation, the investigators determined that the serum miRNA signature correlated with the impact of radiation on animal health rather than the radiation dose. Finally, using humanized mice that had been engrafted with human CD34+ HSCs, they determined that the serum miRNA signature indicated radiation-induced injury to the human bone marrow cells.

"After a radiation release, there is currently no way to tell who was exposed and who was not, and if someone was exposed, is it lethal or not?" said senior author Dr. Dipanjan Chowdhury, a principal investigator in radiation oncology at Dana-Farber Cancer Institute. "Drugs that can limit bone marrow damage are available but, to be effective, must be given before the appearance of radiation symptoms."

The paper was published in the May 13, 2015, online edition of the journal Science Translational Medicine.

Related Links:

Dana-Farber Cancer Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Neonatal Heel Incision Device
Tenderfoot

Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more